Document text
Principal Investigator: Brian Frederick Pickering
Organization: CHIMERNA THERAPEUTICS INC.
Fiscal Year: 2024
Award: $297,608
Funding agency: National Center for Advancing Translational Sciences
SUMMARY:
Circular RNAs (circRNAs) are a novel class of RNAs that hold immense potential as therapeutics due to
their unique cellular functions. However, the challenges associated with their synthesis and purification have
impeded their research and development. Chimerna proposes to develop a platform technology using yeast
to manufacture high-quality circRNAs for use in research, therapeutics, and diagnostics. The proposed
technology builds upon Chimerna's Tornado technology for expressing RNAs as a circle in cells. When
used in E. coli, the Tornado technology results in the production of RNA at high levels not previously seen
with conventional linear RNAs. The stability of circular RNA allows it to accumulate to high levels in E. coli,
and also confers high stability in vitro and when transfected into mammalian cells, thus mitigating the
persistent degradation problem of conventional linear RNAs. The project also utilizes a proprietary affinity
tag that is encoded into the circRNA making downstream purification easier. This technology resolves key
problems associated with current circular RNA synthesis methods that use in vitro transcription for
production. However, production of circRNA in E. coli results in high levels of LPS, which is difficult to
remove and not acceptable for therapeutic indications. The current proposal aims to engineer a yeast strain
capable of producing circRNAs at high yields. Unlike bacteria, yeast do not contain LPS, which is difficult to
remove in downstream purification applications. Moreover, yeast has been extensively used for
manufacturing many bioactive compounds such as proteins and lipids. This makes yeast an ideal organism
in which to develop a circRNA manufacturing platform. The specific aims of the project are: (1) - To
engineer a yeast strain that can be induced to express circular RNA at high yields: This aim involves
engineering multiple yeast strains to produce circRNAs and testing their yield under various inducible
promoters. The yeast strain will be further optimized by introducing RNA processing enzymes required for
maximum circularization efficiency; (2) To benchmark circRNA manufacturing to existing manufacturing
technologies: The second aim of the project involves comparing the yield and cost per gram of RNA
produced in yeast versus traditional IVT. The researchers will also examine protein expression and RNA
half-life from a circular mRNA versus a linear mRNA for total protein output in mammalian cells. Finally, they
will measure inflammatory responses to transfected circRNAs versus linear mRNAs. Taken together, the
development of a yeast manufacturing platform for synthesizing circRNAs holds immense promise for the
production of this highly important type of RNA. The proposed technology will greatly reduce the cost of
producing circRNAs while also simplifying the purification and downstream processing. This new
manufacturing platform will accelerate the entry of circRNAs for medical use, thereby advancing the field of
RNA therapeutics.
Terms: <2019-nCoV vaccine><Acceleration><Affinity><Attention><Bacteria><Benchmarking><Best Practice Analysis><Binding><Biotech><Biotechnology><COVID-19 vaccine><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromatography><Development><Development and Research><Dextrans><Diagnostic><E coli><E. coli><Endotoxins><Engineering><Enzyme Gene><Enzymes><Escherichia coli><Functional RNA><Gel><Gene Transcription><Genetic Transcription><Goals><Guide RNA><Half-Life><IRES><In Vitro><Inflammatory Response><Internal Ribosome Entry Segment><Internal Ribosome Entry Site><Investigators><Lipids><Mammalian Cell><Measures><Medical><Messenger RNA><Methods><Modification><Molecular Interaction><Non-Coding><Non-Coding RNA><Non-Polyadenylated RNA><Non-translated RNA><Noncoding RNA><Nontranslated RNA><Organism><Output><Porifera><Production><Proteins><R & D><R&D><RNA><RNA Expression><RNA Gene Products><RNA Processing><RNA based therapeutics><RNA based therapy><RNA chemical synthesis><RNA synthesis><RNA therapy><RNA vaccine><RNA-based vaccine><Reaction><Research><Research Personnel><Researchers><Ribonucleic Acid><Ribosome Entry Site><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Specificity><Sponges><Subcellular Process><System><Technology><Testing><Therapeutic><Time><Tornadoes><Transcript><Transcription><Transfection><Untranslated RNA><Yeasts><aptamer><benchmark><chemical synthesis><circular RNA><closed circular RNA><cofactor><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cost><cost effective><developmental><dextran><fabrication technology><gRNA><living system><mRNA><mRNA vaccine><mRNA-based vaccine><manufacture><manufacturing technology><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><noncoding><novel><promoter><promotor><protein expression><research and development><sephadex><success><supply chain><technology platform><technology system><therapeutic RNA><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>